192 related articles for article (PubMed ID: 31726691)
1. Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer.
Carafa V; Poziello A; Della Torre L; Giovannelli P; Di Donato M; Safadeh E; Yu Z; Baldi A; Castoria G; Tomaselli D; Mai A; Rotili D; Nebbioso A; Altucci L
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726691
[TBL] [Abstract][Full Text] [Related]
2. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
[TBL] [Abstract][Full Text] [Related]
3. Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies.
Mellini P; Carafa V; Di Rienzo B; Rotili D; De Vita D; Cirilli R; Gallinella B; Provvisiero DP; Di Maro S; Novellino E; Altucci L; Mai A
ChemMedChem; 2012 Nov; 7(11):1905-8. PubMed ID: 24155041
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in inhibitors of sirtuin1/2: an update and perspective.
Zhou Z; Ma T; Zhu Q; Xu Y; Zha X
Future Med Chem; 2018 Apr; 10(8):907-934. PubMed ID: 29642711
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines.
Ceballos MP; Decándido G; Quiroga AD; Comanzo CG; Livore VI; Lorenzetti F; Lambertucci F; Chazarreta-Cifre L; Banchio C; Alvarez ML; Mottino AD; Carrillo MC
Toxicol Lett; 2018 Jun; 289():63-74. PubMed ID: 29545174
[TBL] [Abstract][Full Text] [Related]
6. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.
Lara E; Mai A; Calvanese V; Altucci L; Lopez-Nieva P; Martinez-Chantar ML; Varela-Rey M; Rotili D; Nebbioso A; Ropero S; Montoya G; Oyarzabal J; Velasco S; Serrano M; Witt M; Villar-Garea A; Imhof A; Mato JM; Esteller M; Fraga MF
Oncogene; 2009 Feb; 28(6):781-91. PubMed ID: 19060927
[TBL] [Abstract][Full Text] [Related]
7. The Fungal Metabolite Eurochevalierine, a Sequiterpene Alkaloid, Displays Anti-Cancer Properties through Selective Sirtuin 1/2 Inhibition.
Schnekenburger M; Mathieu V; Lefranc F; Jang JY; Masi M; Kijjoa A; Evidente A; Kim HJ; Kiss R; Dicato M; Han BW; Diederich M
Molecules; 2018 Feb; 23(2):. PubMed ID: 29401749
[TBL] [Abstract][Full Text] [Related]
8. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins.
Botta G; De Santis LP; Saladino R
Curr Med Chem; 2012; 19(34):5871-84. PubMed ID: 22998567
[TBL] [Abstract][Full Text] [Related]
9. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer.
Hoffmann G; Breitenbücher F; Schuler M; Ehrenhofer-Murray AE
J Biol Chem; 2014 Feb; 289(8):5208-16. PubMed ID: 24379401
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
[TBL] [Abstract][Full Text] [Related]
11. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines.
Kozako T; Mellini P; Ohsugi T; Aikawa A; Uchida YI; Honda SI; Suzuki T
BMC Cancer; 2018 Aug; 18(1):791. PubMed ID: 30081901
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
Shah AA; Ito A; Nakata A; Yoshida M
Biol Pharm Bull; 2016; 39(10):1739-1742. PubMed ID: 27725455
[TBL] [Abstract][Full Text] [Related]
13. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
14. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
Galli U; Mesenzani O; Coppo C; Sorba G; Canonico PL; Tron GC; Genazzani AA
Eur J Med Chem; 2012 Sep; 55():58-66. PubMed ID: 22835719
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress on the Discovery of Sirt2 Inhibitors for the Treatment of Various Cancers.
Wang T; Xu Z; Lu Y; Shi J; Liu W; Zhang C; Jiang Z; Qi B; Bai L
Curr Top Med Chem; 2019; 19(12):1051-1058. PubMed ID: 31074370
[TBL] [Abstract][Full Text] [Related]
16. Anticancer agents targeted to sirtuins.
Kozako T; Suzuki T; Yoshimitsu M; Arima N; Honda S; Soeda S
Molecules; 2014 Dec; 19(12):20295-313. PubMed ID: 25486244
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL).
Bhalla S; Gordon LI
Cancer Biol Ther; 2016; 17(3):300-9. PubMed ID: 26794150
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.
Eren G; Bruno A; Guntekin-Ergun S; Cetin-Atalay R; Ozgencil F; Ozkan Y; Gozelle M; Kaya SG; Costantino G
J Mol Graph Model; 2019 Jun; 89():60-73. PubMed ID: 30870650
[TBL] [Abstract][Full Text] [Related]
19. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.
Huhtiniemi T; Suuronen T; Lahtela-Kakkonen M; Bruijn T; Jääskeläinen S; Poso A; Salminen A; Leppänen J; Jarho E
Bioorg Med Chem; 2010 Aug; 18(15):5616-25. PubMed ID: 20630764
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
